Clinical trial
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or…
NCT00262990 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00262990 |
|---|---|
| Title | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer |
| Official title | A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms |
| Intervention type | Drug |
| Interventions | EPO906 (Patupilone), doxorubicin |
| Enrollment | 829 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2010 |
| First posted | Dec 7, 2005 |
| Last update posted | Dec 17, 2020 |
| Countries | Australia, Canada, Denmark, Finland, France, Greece, Italy, Poland, South Africa, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: